1. A pharmaceutical composition characterized in that it comprises an activated-potentiated form of antibodies to histamine, the activated-potentiated form of antibodies to tumor necrosis factor-alpha and the activated-potentiated form of antibodies to brain-specific protein S-100.2. A pharmaceutical composition according to claim 1, characterized in that the activated-potentiated form of antibodies to histamine, the activated-potentiated form of antibodies to tumor necrosis factor-alpha and the activated-potentiated form of antibodies to S-100 brain-specific proteins are used in the activated-potentiated form aqueous or hydroalcoholic solution obtained in the process of successive dilutions of multiple respective matrix solution of antibodies in an aqueous or aqueous-alcoholic solvent, and an intermediate th external mechanical impact-shaking each razvedeniya.3. A pharmaceutical composition according to claim 1 or 2, characterized in that it is formed in a solid dosage form and comprises an effective amount of saturated activated-potentiated form of antibodies to histamine, the activated-potentiated form of antibodies to tumor necrosis factor-alpha and the activated-potentiated form of antibodies to brain-specific protein S-100 neutral carrier granules and pharmaceutically acceptable dobavki.4. A pharmaceutical composition according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solutions of the activated-potentiated forms of antibodies to histamine, tumor necrosis factor-alpha and to a brain-specific protein S-100 prepared by repeated successive pa1. Фармацевтическая композиция, характеризующаяся тем, что содержит активированную-потенцированную форму антител к гистамину, активированную-потенцированную форму антител к фактору некроза опухоли-альфа и активированную-потенцированную форму антител к мозгоспецифическому белку S-100.2. Фармацевтическая композиция по п.1, характеризующаяся тем, что активированную-потенцированную форму антител к ги
